Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT)

Oncogene

Volumn 32, Issue 1, 2013, Pages 50-60

  Serrano, I ^a   Mcdonald, P C ^a   Lock, F E ^a   Dedhar, S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

breast epithelial cells; cancer; EMT; ILK Rictor complex; integrin linked kinase; Rictor

Indexed keywords

INTEGRIN LINKED KINASE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BREAST EPITHELIUM; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1;

GASTROPODA; MAMMALIA;

EID: 84871971370     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.30     Document Type: Article

References (49)

1. McPhee TR, McDonald PC, Oloumi A, Dedhar S. Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev Dyn 2008; 237: 2737-2747.
2. Savagner P. Leaving the neighborhood: Molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23: 912-923.
3. Papanikolaou S, Bravou V, Gyftopoulos K, Nakas D, Repanti M, Papadaki H. ILK expression in human basal cell carcinoma correlates with epithelial-mesenchymal transition markers and tumour invasion. Histopathology 2010; 56: 799-809.
4. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12: 27-36.
5. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11: 97-105.
6. Li Y, Tan X, Dai C, Stolz DB, Wang D, Liu Y. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 1907-1918.
7. Fielding AB, Dobreva I, Dedhar S. Beyond focal adhesions: Integrin-linked kinase associates with tubulin and regulates mitotic spindle organization. Cell Cycle 2008; 7: 1899-1906.
8. McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase-essential roles in physiology and cancer biology. J Cell Sci 2008; 121: 3121-3132.
9. Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA et al. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. CancerRes 2006; 66: 393-403.
10. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V et al. Rictor andintegrin-linked kinase interact and regulate Akt phosphorylation and cancer cellsurvival. Cancer Res 2008; 68: 1618-1624.
11. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting thecellular signaling symphony. J Biol Chem 2010; 285: 14071-14077.
12. Treins C, Warne PH, Magnuson MA, Pende M, Downward J. Rictor is a novel targetof p70 S6 kinase-1. Oncogene 2010; 29: 1003-1016.
13. Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 2010; 30:908-921.
14. Boulbes D, Chen CH, Shaikenov T, Agarwal NK, Peterson TR, Addona TA et al.Rictor phosphorylation on the Thr-1135 site does not require mammalian targetof rapamycin complex 2. Mol Cancer Res 2010; 8: 896-906.
15. Kavvadas P, Kypreou KP, Protopapadakis E, Prodromidi E, Sideras P, Charonis AS.Integrin-linked kinase (ILK) in pulmonary fibrosis. Virchows Arch 2010; 457:563-575.
16. Matsui Y, Assi K, Ogawa O, Raven PA, Dedhar S, Gleave ME et al. The importanceof integrin-linked kinase in the regulation of bladder cancer invasion. Int J Cancer 2012; 130: 521-531.
17. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 2001; 114: 1125-1136.
18. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelialmesenchymal cell transition. Mol Biol Cell 2005; 16: 1987-2002.
19. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51-63.
20. Futterman MA, Garcia AJ, Zamir EA. Evidence for partial epithelial-to-mesenchymal transition (pEMT) and recruitment of motile blastoderm edge cells during avian epiboly. Dev Dyn 2011; 240: 1502-1511.
21. Zhao JH, Luo Y, Jiang YG, He DL, Wu CT. Knockdown of beta-catenin through shRNA cause a reversal of EMT and metastatic phenotypes induced by HIF-1alpha. Cancer Invest 2011; 29: 377-382.
22. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R et al. Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. Lab Invest 2011; 91: 1443-1458.
23. Tan C, Costello P, Sanghera J, Dominguez D, Baulida J, de Herreros AG et al. Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/ Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene 2001; 20: 133-140.
24. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis2011; 32: 1299-1304.
25. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
26. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246-3256.
27. Gao H, Steffen MC, Ramos KS. Osteopontin regulates alpha-smooth muscle actin and calponin in vascular smooth muscle cells. Cell Biol Int 2012; 36: 155-161.
28. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
29. Jing Y, Han Z, Zhang S, Liu Y, Wei L. Epithelial-mesenchymal transition in tumor microenvironment. Cell Biosci 2011; 1: 29.
30. Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem 2009; 284: 22825-22833.
31. Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29: 5657-5670.
32. Hong-Brown LQ, Brown CR, Navaratnarajah M, Huber DS, Lang CH. Alcoholinduced modulation of Rictor and mTORC2 activity in C2C12 myoblasts. Alcohol Clin Exp Res 2011; 35: 1445-1453.
33. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci 1999; 112: 4557-4568.
34. Lamb RF, Hennigan RF, Turnbull K, Katsanakis KD, MacKenzie ED, Birnie GD et al. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 1997; 17: 963-976.
35. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 2001; 276: 46707-46713.
36. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275: 36803-36810.
37. Lee YI, Kwon YJ, Joo CK. Integrin-linked kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition. Biochem Biophys Res Commun 2004; 316: 997-1001.
38. Dong C, Li Z, Alvarez Jr. R, Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 2000; 5: 27-34.
39. Gil D, Ciolczyk-Wierzbicka D, Dulinska-Litewka J, Zwawa K, McCubrey JA, Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelialmesenchymal transition (EMT). Adv Enzyme Regul 2011; 51: 195-207.
40. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
41. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 2001; 153: 1161-1174.
42. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial-mesenchymal transition. J Cell Biol 2005; 168: 29-33.
43. Doble BW, Woodgett Jr. Role of glycogen synthase kinase-3 in cell fate and epithelial-mesenchymal transitions. Cells Tissues Organs 2007; 185: 73-84.
44. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004; 6: 931-940.
45. Dzwonek J, Preobrazhenska O, Cazzola S, Conidi A, Schellens A, van Dinther M et al. Smad3 is a key nonredundant mediator of transforming growth factor beta signaling in Nme mouse mammary epithelial cells. Mol Cancer Res 2009; 7: 1342-1353.
46. de Bessa Garcia SA, Pereira MC, Nagai MA. Expression pattern of the pro-apoptotic gene PAR-4 during the morphogenesis of MCF-10A human mammary epithelial cells. Cancer Microenviron 2010; 4: 33-38.
47. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002; 4: 204-217.
48. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
49. Garcia G, Rodriguez-Puyol M, Alajarin R, Serrano I, Sanchez-Alonso P, Griera M et al. Losartan-antioxidant hybrids: novel molecules for the prevention of hypertension-induced cardiovascular damage. J Med Chem 2009; 52: 7220-7227.